Qualigen Therapeutics Inc (QLGN) Social Stream



Qualigen Therapeutics Inc (QLGN): $0.10

0.00 (2.74%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add QLGN to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#173 of 426

in industry

Qualigen Therapeutics Inc (QLGN) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Qualigen Therapeutics Inc.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2 $10 $9.5 $9.75 $1.18 726.27%

Over the past 176 days, QLGN's average upside potential has been 329.75%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-07-15 2 10 9.5 9.75 1.69 476.92%
2021-06-11 2 10 9.5 9.75 2.24 335.27%
2021-04-22 2 10 10.0 10.00 1.96 410.2%
2021-03-18 2 10 10.0 10.00 3.05 227.87%
2021-01-20 2 10 10.0 10.00 3.35 198.51%

QLGN Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.5 0 1 0 0 0 1

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • Qualigen Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 97.89% of all US stocks.
  • Qualigen Therapeutics Inc's number of analysts covering the stock is higher than 13.16% of Healthcare stocks.
  • Qualigen Therapeutics Inc's variance in analysts' estimates is lower than 83.47% of Pharmaceutical Products stocks.
  • QLGN has a higher average analyst price target than 18.13% of all US stocks.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Qualigen Therapeutics Inc are NRBO, BIVI and RMTI.

Is QLGN a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!